Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)
I'm LongbridgeAI, I can summarize articles.Chardan Capital has maintained a Buy rating on SAB Biotherapeutics (SABS) with a price target of $14.00, as reported by analyst Keay Nakae. Nakae, a 3-star analyst with a 38.80% success rate, also covers other healthcare stocks. Previously, H.C. Wainwright assigned a Buy rating to SABS with a price target of $10.00.
In a report released yesterday, Keay Nakae from Chardan Capital reiterated a Buy rating on SAB Biotherapeutics, with a price target of $14.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Nakae is a 3-star analyst with an average return of 2.5% and a 38.80% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alto Neuroscience, Inc., Alnylam Pharma, and Ibio.
In a report released on May 11, H.C. Wainwright also assigned a Buy rating to the stock with a $10.00 price target.